Olivia Ware
Director/Board Member bij REVANCE THERAPEUTICS, INC.
Vermogen: 82 041 $ op 31-03-2024
Profiel
Olivia C.
Ware is currently an Independent Director at Revance Therapeutics, Inc., Arcellx, Inc., and Contineum Therapeutics, Inc. She previously worked as a Director at Ambrx, Inc. and held the position of Independent Director at Ambrx Biopharma Cayman, Inc. from 2021 to 2022.
Olivia also served as the Senior VP-US Market & Franchise Development at Proteus Digital Health, Inc. from 2018 to 2019 and as the Senior Vice President at Principia Biopharma, Inc. from 2019 to 2021.
Additionally, she was the Chief Commercial Officer at LadRx Corp.
from 2016 to 2017.
Olivia completed her undergraduate degree at Davidson College and holds an MBA from The University of North Carolina at Chapel Hill.
Ms. Ware's current job(s) include Independent Director at Revance Therapeutics, Inc., Arcellx, Inc., and Director at Contineum Therapeutics, Inc.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
08-03-2024 | 16 675 ( 0.02% ) | 82 041 $ | 31-03-2024 | |
04-04-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Olivia Ware
Bedrijven | Functie | Begin |
---|---|---|
REVANCE THERAPEUTICS, INC. | Director/Board Member | 06-03-2021 |
ARCELLX, INC. | Director/Board Member | 16-05-2022 |
CONTINEUM THERAPEUTICS, INC. | Director/Board Member | 01-03-2024 |
Eerdere bekende functies van Olivia Ware
Bedrijven | Functie | Einde |
---|---|---|
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Director/Board Member | 01-06-2022 |
PRINCIPIA BIOPHARMA INC. | Corporate Officer/Principal | 01-03-2021 |
Proteus Digital Health, Inc.
Proteus Digital Health, Inc. Pharmaceuticals: MajorHealth Technology Proteus Digital Health, Inc. develops medicine products and therapeutic devices. It provides digital health products that collect behavioral, physiologic, and therapeutic metrics, such as medication adherence, heart rate, sleep patterns, physical activity, and stress levels into personal management tools delivered to the mobile devices of consumers. The company was founded by Andrew M. Thompson, George M. Savage, and Mark J. Zdeblick in 2001 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | 01-01-2019 |
LADRX CORPORATION | Corporate Officer/Principal | 01-01-2017 |
AMBRX INC | Director/Board Member | - |
Opleiding van Olivia Ware
Davidson College | Undergraduate Degree |
The University of North Carolina at Chapel Hill | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
LADRX CORPORATION | Health Technology |
REVANCE THERAPEUTICS, INC. | Health Technology |
ARCELLX, INC. | Health Technology |
CONTINEUM THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Proteus Digital Health, Inc.
Proteus Digital Health, Inc. Pharmaceuticals: MajorHealth Technology Proteus Digital Health, Inc. develops medicine products and therapeutic devices. It provides digital health products that collect behavioral, physiologic, and therapeutic metrics, such as medication adherence, heart rate, sleep patterns, physical activity, and stress levels into personal management tools delivered to the mobile devices of consumers. The company was founded by Andrew M. Thompson, George M. Savage, and Mark J. Zdeblick in 2001 and is headquartered in Redwood City, CA. | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Ambrx, Inc.
Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |